Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results
暂无分享,去创建一个
[1] B. Chauffert,et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Albert C. Koong,et al. Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma , 2014, Cancer.
[3] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[4] T. Briere,et al. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.
[5] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[6] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[7] W. Shi,et al. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer , 2017, Acta oncologica.
[8] Jeffrey E. Lee,et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Jim Zhong,et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation , 2017, Cancer.
[10] H. von der Maase,et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[11] David Goldstein,et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.
[12] T. Desser,et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. , 2008, International journal of radiation oncology, biology, physics.
[13] Parag J. Parikh,et al. Poster ViewingHigh Dose Adaptive MRI Guided Radiation Therapy Improves Overall Survival of Inoperable Pancreatic Cancer , 2017 .
[14] J P Cuijpers,et al. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] Gabriel O Sawakuchi,et al. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. , 2016, International journal of radiation oncology, biology, physics.
[16] Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. , 1988, Journal of the National Cancer Institute.
[17] T. Conroy,et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.
[18] Alison P. Klein,et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] David Cella,et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Sasa Mutic,et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[21] P. Engstrom,et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.